BCRX
Price
$9.96
Change
-$0.01 (-0.10%)
Updated
Jun 18 closing price
Capitalization
2.08B
42 days until earnings call
CLDX
Price
$20.82
Change
+$0.76 (+3.79%)
Updated
Jun 18 closing price
Capitalization
1.38B
49 days until earnings call
Interact to see
Advertisement

BCRX vs CLDX

Header iconBCRX vs CLDX Comparison
Open Charts BCRX vs CLDXBanner chart's image
BioCryst Pharmaceuticals
Price$9.96
Change-$0.01 (-0.10%)
Volume$3.07M
Capitalization2.08B
Celldex Therapeutics
Price$20.82
Change+$0.76 (+3.79%)
Volume$745.71K
Capitalization1.38B
BCRX vs CLDX Comparison Chart in %
Loading...
BCRX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
CLDX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
BCRX vs. CLDX commentary
Jun 19, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BCRX is a Hold and CLDX is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jun 19, 2025
Stock price -- (BCRX: $9.96 vs. CLDX: $20.82)
Brand notoriety: BCRX: Notable vs. CLDX: Not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: BCRX: 61% vs. CLDX: 78%
Market capitalization -- BCRX: $2.08B vs. CLDX: $1.38B
BCRX [@Biotechnology] is valued at $2.08B. CLDX’s [@Biotechnology] market capitalization is $1.38B. The market cap for tickers in the [@Biotechnology] industry ranges from $335.78B to $0. The average market capitalization across the [@Biotechnology] industry is $2.38B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

BCRX’s FA Score shows that 0 FA rating(s) are green whileCLDX’s FA Score has 0 green FA rating(s).

  • BCRX’s FA Score: 0 green, 5 red.
  • CLDX’s FA Score: 0 green, 5 red.
According to our system of comparison, BCRX is a better buy in the long-term than CLDX.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

BCRX’s TA Score shows that 4 TA indicator(s) are bullish while CLDX’s TA Score has 5 bullish TA indicator(s).

  • BCRX’s TA Score: 4 bullish, 4 bearish.
  • CLDX’s TA Score: 5 bullish, 2 bearish.
According to our system of comparison, CLDX is a better buy in the short-term than BCRX.

Price Growth

BCRX (@Biotechnology) experienced а -6.13% price change this week, while CLDX (@Biotechnology) price change was +1.96% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +7.32%. For the same industry, the average monthly price growth was +13.75%, and the average quarterly price growth was +8.90%.

Reported Earning Dates

BCRX is expected to report earnings on Jul 31, 2025.

CLDX is expected to report earnings on Aug 07, 2025.

Industries' Descriptions

@Biotechnology (+7.32% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
BCRX($2.08B) has a higher market cap than CLDX($1.38B). BCRX YTD gains are higher at: 32.447 vs. CLDX (-17.610). BCRX has higher annual earnings (EBITDA): 47.6M vs. CLDX (-213.94M). CLDX has more cash in the bank: 673M vs. BCRX (295M). CLDX has less debt than BCRX: CLDX (3.43M) vs BCRX (795M). BCRX has higher revenues than CLDX: BCRX (503M) vs CLDX (7.56M).
BCRXCLDXBCRX / CLDX
Capitalization2.08B1.38B151%
EBITDA47.6M-213.94M-22%
Gain YTD32.447-17.610-184%
P/E RatioN/AN/A-
Revenue503M7.56M6,654%
Total Cash295M673M44%
Total Debt795M3.43M23,191%
FUNDAMENTALS RATINGS
BCRX vs CLDX: Fundamental Ratings
BCRX
CLDX
OUTLOOK RATING
1..100
5757
VALUATION
overvalued / fair valued / undervalued
1..100
34
Fair valued
55
Fair valued
PROFIT vs RISK RATING
1..100
7465
SMR RATING
1..100
10094
PRICE GROWTH RATING
1..100
4163
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
5085

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

BCRX's Valuation (34) in the Biotechnology industry is in the same range as CLDX (55). This means that BCRX’s stock grew similarly to CLDX’s over the last 12 months.

CLDX's Profit vs Risk Rating (65) in the Biotechnology industry is in the same range as BCRX (74). This means that CLDX’s stock grew similarly to BCRX’s over the last 12 months.

CLDX's SMR Rating (94) in the Biotechnology industry is in the same range as BCRX (100). This means that CLDX’s stock grew similarly to BCRX’s over the last 12 months.

BCRX's Price Growth Rating (41) in the Biotechnology industry is in the same range as CLDX (63). This means that BCRX’s stock grew similarly to CLDX’s over the last 12 months.

BCRX's P/E Growth Rating (100) in the Biotechnology industry is in the same range as CLDX (100). This means that BCRX’s stock grew similarly to CLDX’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
BCRXCLDX
RSI
ODDS (%)
Bearish Trend 1 day ago
77%
N/A
Stochastic
ODDS (%)
Bullish Trend 1 day ago
82%
Bullish Trend 1 day ago
76%
Momentum
ODDS (%)
Bearish Trend 1 day ago
79%
Bullish Trend 1 day ago
82%
MACD
ODDS (%)
Bearish Trend 1 day ago
85%
Bullish Trend 1 day ago
80%
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
80%
Bullish Trend 1 day ago
80%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
83%
Bullish Trend 1 day ago
79%
Advances
ODDS (%)
Bullish Trend 11 days ago
79%
N/A
Declines
ODDS (%)
Bearish Trend 1 day ago
80%
Bearish Trend 3 days ago
81%
BollingerBands
ODDS (%)
Bullish Trend 1 day ago
90%
Bearish Trend 1 day ago
86%
Aroon
ODDS (%)
Bullish Trend 1 day ago
90%
Bullish Trend 1 day ago
76%
View a ticker or compare two or three
Interact to see
Advertisement
BCRX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
CLDX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
AMAKX9.69N/A
N/A
American Century Small Cap Dividend R6
PRLAX20.29N/A
N/A
T. Rowe Price Latin America
VEXMX141.26N/A
N/A
Vanguard Extended Market Index Investor
PLARX10.43N/A
N/A
Principal SmallCap Value II R5
SPISX64.39N/A
N/A
Invesco S&P 500 Index R6

BCRX and

Correlation & Price change

A.I.dvisor indicates that over the last year, BCRX has been loosely correlated with VCYT. These tickers have moved in lockstep 46% of the time. This A.I.-generated data suggests there is some statistical probability that if BCRX jumps, then VCYT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To BCRX
1D Price
Change %
BCRX100%
-0.10%
VCYT - BCRX
46%
Loosely correlated
+0.22%
CRNX - BCRX
40%
Loosely correlated
-1.13%
HOWL - BCRX
40%
Loosely correlated
+2.48%
CLDX - BCRX
39%
Loosely correlated
+3.79%
VKTX - BCRX
39%
Loosely correlated
-0.57%
More

CLDX and

Correlation & Price change

A.I.dvisor indicates that over the last year, CLDX has been loosely correlated with BEAM. These tickers have moved in lockstep 53% of the time. This A.I.-generated data suggests there is some statistical probability that if CLDX jumps, then BEAM could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CLDX
1D Price
Change %
CLDX100%
+3.79%
BEAM - CLDX
53%
Loosely correlated
+1.92%
ATXS - CLDX
50%
Loosely correlated
+3.33%
CRNX - CLDX
50%
Loosely correlated
-1.13%
RVMD - CLDX
50%
Loosely correlated
+2.02%
DNLI - CLDX
49%
Loosely correlated
-3.63%
More